Skip to main content

Table 1

From: Tumor mica status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer

Variable   N m DFS p-value m OS p-value
Sex Male 66 42.0 0.373 44.0 0.229
  Female 29 42.0   50.0  
Age <65 67 41.0 0.588 48.0 0.464
  ≥65 28 43.0   43.0  
Histological grade G1-G2 48 43.0 0.480 48.0 0.556
  G3-G4 47 31.0   43.0  
Stage II 44 50.0 0.001 51.0 0.006
  III 51 36.0   41.0  
Adjuvant Chemotherapy Xelox, Folfox4 57 41.0 0.250 43.0 0.257
  PF 38 42.0   46.0  
CIK cycles <5 54 40.0 0.046 42.0 0.075
  ≥5 41 48.0   50.0  
MICA status High 38 46.0 0.027 48.0 0.031
  Low 57 41.0   42.0